2F-QMPSB

2F-QMPSB (SGT-13) is an arylsulfonamide-based synthetic cannabinoid that is a fluorinated derivative of QMPSB and has been sold as a designer drug.[1] Its identification was first reported by a forensic laboratory in Italy in January 2019,[2] and it was made illegal in Latvia shortly afterwards.[3][4] Fluorination of the tail group is a common strategy to increase potency at cannabinoid receptors which is seen in many related series of compounds.[5][6]

2F-QMPSB
Legal status
Legal status
Identifiers
IUPAC name
  • 8-quinolinyl 4-methyl-3-[(4,4-difluoropiperidin-1-yl)sulfonyl]benzoate
PubChem CID
ChemSpider
Chemical and physical data
FormulaC22H20F2N2O4S
Molar mass446.467 g·mol−1
3D model (JSmol)
SMILES
  • FC1(F)CCN(CC1)S(=O)(=O)c2cc(ccc2C)C(=O)Oc4cccc3cccnc34
InChI
  • InChI=1S/C22H20F2N2O4S/c1-15-7-8-17(14-19(15)31(28,29)26-12-9-22(23,24)10-13-26)21(27)30-18-6-2-4-16-5-3-11-25-20(16)18/h2-8,11,14H,9-10,12-13H2,1H3
  • Key:JOSWCKYCXJMLNM-UHFFFAOYSA-N

See also

References

  1. Tsochatzis ED, Alberto Lopes J, Holland MV, Reniero F, Palmieri G, Guillou C (2021). "Identification and Analytical Characterization of a Novel Synthetic Cannabinoid-Type Substance in Herbal Material in Europe". Molecules. 26 (4): 793. doi:10.3390/molecules26040793.
  2. "NPS2019". Belgian Early Warning System on Drugs (BEWSD).
  3. Centre for Disease Prevention and Control (17 January 2019). "Par aizlieguma noteikšanu vielai 2F-QMPSB un tās saturošiem izstrādājumiem" [On the Prohibition of 2F-QMPSB and Articles Containing It]. Latvian Journal: Legal Acts of the Republic of Latvia (in Latvian).
  4. "Уважаемые эксперты" [Dear experts]. Aipsin Drugs (in Russian).
  5. Banister SD, Stuart J, Kevin RC, Edington A, Longworth M, Wilkinson SM, et al. (August 2015). "Effects of bioisosteric fluorine in synthetic cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135". ACS Chemical Neuroscience. 6 (8): 1445–58. doi:10.1021/acschemneuro.5b00107. PMID 25921407.
  6. Yang SW, Smotryski J, Matasi J, Ho G, Tulshian D, Greenlee WJ, et al. (January 2011). "Structure-activity relationships of 2,4-diphenyl-1H-imidazole analogs as CB2 receptor agonists for the treatment of chronic pain". Bioorganic & Medicinal Chemistry Letters. 21 (1): 182–5. doi:10.1016/j.bmcl.2010.11.044. PMID 21115245.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.